- Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing
- The round led by Northpond Ventures and Cowen Healthcare Investments, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital
- The company also intends to use the funds to advance its lead therapeutic candidates into clinical development
- Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease
- Centyrins are small, stable, engineered human proteins with several properties that make them suited to target receptors on specific cells
- Then the company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates
